[Ip-health] The variables in Dr. Peter Bach's Drug Abacus

Jamie Love james.love at keionline.org
Fri Jun 19 12:35:51 PDT 2015

On Fri, Jun 19, 2015 at 3:31 PM, Ruth Lopert <ruth.lopert at gmail.com> wrote:

> There is no inherent value in novelty. There are plenty of examples of
> drugs with novel mechanisms of action that are no more effective and even
> less effective than drugs in the classes that preceded them. Innovation
> that addresses an unmet or inadequately met clinical need is of value, but
> not novelty per se,
Ruth,  ​I think there is a both a value associated with novelty, and risk.
Novel approaches may expand the tools available and stimulate new research
paths.  But novel approaches are probably also more risky, and might
benefit from higher rewards, all other things equal or relative.


More information about the Ip-health mailing list